Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma.

Gupta D, Gunter MJ, Yang K, Lee S, Zuckerwise L, Chen LM, Goldberg GL, Huang GS.

Int J Gynecol Cancer. 2011 Apr;21(3):529-34. doi: 10.1097/IGC.0b013e31821091b5.

PMID:
21436701
2.

Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma.

Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, Rueda B, Goodman A, del Carmen MG.

Gynecol Oncol. 2008 Sep;110(3):293-8. doi: 10.1016/j.ygyno.2008.05.027. Epub 2008 Jul 21.

PMID:
18644620
3.

Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.

Mury D, Woelber L, Jung S, Eulenburg C, Choschzick M, Witzel I, Schwarz J, Jaenicke F, Mahner S.

J Cancer Res Clin Oncol. 2011 Jul;137(7):1131-7. doi: 10.1007/s00432-011-0977-1. Epub 2011 Feb 23.

PMID:
21344262
4.

An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).

Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, O'Malley DM, Tuller ER, Rose PG, Havrilesky LJ, Moore KN, Huh WK, Axtell AE, Kelley JL, Zanotti KM; UPSC Consortium.

Gynecol Oncol. 2009 Nov;115(2):244-8. doi: 10.1016/j.ygyno.2009.07.030. Epub 2009 Aug 26.

PMID:
19712966
5.

[Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy].

Xue DB, Ding LJ, Xia AL, Chen D, Xia HP, Teng XD, Xu ST, Zhang SJ, Ren XC.

Zhonghua Bing Li Xue Za Zhi. 2010 Oct;39(10):671-4. Chinese.

PMID:
21176532
6.

CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.

Tseng PC, Sprance HE, Carcangiu ML, Chambers JT, Schwartz PE.

Obstet Gynecol. 1989 Sep;74(3 Pt 1):384-7.

PMID:
2761916
7.

Para-aortic lymphadenectomy in the management of preoperative grade 1 endometrial cancer confined to the uterine corpus.

Yoon JH, Yoo SC, Kim WY, Chang SJ, Chang KH, Ryu HS.

Ann Surg Oncol. 2010 Dec;17(12):3234-40. doi: 10.1245/s10434-010-1199-5. Epub 2010 Jun 29.

PMID:
20585865
8.

The utility of routine follow-up procedures in the surveillance of uterine cancer: a 20-year institutional review.

Rettenmaier CR, Rettenmaier NB, Wojciechowski T, Abaid LN, Brown Iii JV, Micha JP, Goldstein BH.

Oncology. 2010;79(3-4):262-8. doi: 10.1159/000322502. Epub 2011 Mar 4.

PMID:
21372601
9.

The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer.

Frimer M, Hou JY, McAndrew TC, Goldberg GL, Shahabi S.

Reprod Sci. 2013 Apr;20(4):449-55. doi: 10.1177/1933719112459218. Epub 2012 Sep 20.

10.

The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).

Dietrich CS 3rd, Modesitt SC, DePriest PD, Ueland FR, Wilder J, Reedy MB, Pavlik EJ, Kryscio R, Cibull M, Giesler J, Manahan K, Huh W, Cohn D, Powell M, Slomovitz B, Higgins RV, Merritt W, Hunter J, Puls L, Gehrig P, van Nagell JR Jr.

Gynecol Oncol. 2005 Dec;99(3):557-63. Epub 2005 Sep 8.

PMID:
16154185
11.

Optimal surgical debulking in uterine papillary serous carcinoma affects survival.

Patsavas K, Woessner J, Gielda B, Rotmensch J, Yordan E, Bitterman P, Guirguis A.

Gynecol Oncol. 2011 Jun 1;121(3):581-5. doi: 10.1016/j.ygyno.2010.11.048. Epub 2011 Mar 25.

PMID:
21440290
12.

Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients.

Roelofsen T, Mingels M, Hendriks JC, Samlal RA, Snijders MP, Aalders AL, Bulten J, van Ham MA, Massuger LF.

Int J Biol Markers. 2012 Oct 8;27(3):e263-71. doi: 10.5301/JBM.2012.9346.

PMID:
22865295
13.

Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.

Tchabo NE, McCloskey S, Mashtare TL, Andrews C, Singh AK, Mhawech-Fauceglia P, Odunsi K, Lele S, Jaggernauth W.

Gynecol Oncol. 2009 Nov;115(2):249-56. doi: 10.1016/j.ygyno.2009.07.004. Epub 2009 Aug 18.

PMID:
19692115
14.

Uterine papillary serous cancer: a review of the literature.

del Carmen MG, Birrer M, Schorge JO.

Gynecol Oncol. 2012 Dec;127(3):651-61. doi: 10.1016/j.ygyno.2012.09.012. Epub 2012 Sep 20. Review.

PMID:
23000148
15.

A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome.

Faratian D, Stillie A, Busby-Earle RM, Cowie VJ, Monaghan H.

Int J Gynecol Cancer. 2006 May-Jun;16(3):972-8.

PMID:
16803471
16.

Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?

Kwon JS, Abrams J, Sugimoto A, Carey MS.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):820-4. Epub 2007 Sep 24.

PMID:
17892450
17.

Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.

Kelly MG, O'malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE.

Gynecol Oncol. 2005 Sep;98(3):353-9.

PMID:
16005947
18.

Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma.

Abramovich D, Markman M, Kennedy A, Webster K, Belinson J.

J Cancer Res Clin Oncol. 1999 Dec;125(12):697-8.

PMID:
10592103
19.

Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma.

Sagr ER, Denschlag D, Kerim-Dikeni A, Stanimir G, Gitsch G, Gilbert L.

Anticancer Res. 2007 Mar-Apr;27(2):1213-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk